Tumor microenvironment-driven microRNA dysregulation: Key interactions in colorectal cancer progression

Table 4 MicroRNA’s associated with treatment response and therapeutic outcomes in colorectal cancer[26,86,88,91,93,94,170-186]

miR	Mechanism	Study model	Target	Response therapy	Ref.
miR-153-5p	Overexpression	In vitro	BCL-2	Sensibilize oxaliplatin	He et al[170]
miR-145-5p	Decreased	In vitro	BIRC5, Fli-1	Sensibilize, 5-FU, oxaliplatin	Xie et al[171]
miR-1451	Overexpression	In vitro and in vivo	SNAI1, HDAC4 and ATF4	Sensibilize radiotherapy and 5-FU	Zhao et al[88]; Zhu et al[172]
miR-150-5p	Overexpression	In vitro and in vivo	BIRC5, CASP7, VEGFA	Anti-VEGF	Slattery et al[173]; Chen et al[174]
miR-195-5p	Expression	In vivo	GDPD5	Sensibilize 5-FU	Feng et al[175]
	Overexpression	In vitro	BIRC5, BCL-2, YAP	Sensibilize, doxorrubicin and oxaliplatin	Qu et al[176]; Poel et al[177]
miR20b-5p1	Expression	In vitro and in vivo	CTSS, ADAM9, EGFR, CCND1/CDK4/FOXM1 axis	Sensibilize 5-FU	Fu et al[178]; Yang et al[179]
miR21-3p	Overexpression	In vitro	MDR1 and MRP1	Cisplatin resistance	Dong et al[86]
miR21-5p	Overexpression	In vitro	SATB1, PTEN, MSH2, PDCD4	Chemoresistance (oxaliplatin)	Chen et al[94]
miR497-5p	Overexpression	In vitro and in vivo	KSR1, BCL-2, IGF1-R	Sensibilize 5-FU, oxaliplatin	Poel et al[177]; Wang et al[180]
miR-17-5p	Overexpression	In vitro and in vivo	MFN2, vimentin STAT3, E2F1, HMGA2, SOX4, TWIST1, and EGFR	Resistance oxaliplatin, irinotecan, and fluorouracil	Kim et al[26]; Sun et al[181]
miR-199b-3p; miR-199a-5p	Overexpression	In vitro and in vivo	CRIM1	Resistance cetuximab, sensitive cetuximab	Kim et al[26]; Han et al[93]; Mussnich et al[182]
miR-124	Overexpression	In vitro and in vivo	PRRX1	Sensitive radiotherapy (inhibition PRRX1)	Zhang et al[183]
miR-1226-5p	Overexpression	In vitro	IRF1	Resistance radiotherapy	Choi et al[184]
miR-7-5p	Downregulated	In vitro and in vivo	KLF4	Resistance radiotherapy	Shang et al[185]
miR-16-5p	Downregulated	In vitro	FOXK, PI3K/AKT/mTOR	Resistance radiotherapy	Mousavikia et al[91]
miR-423-5p	Downregulated	In vitro	BCL-2	Resistance radiotherapy	Shang et al[186]

¹Expressed on advanced cancer.

miR: MicroRNA; MDR1: Multidrug resistance-1; MRP1: Multidrug resistance protein 1; PI3K: Phosphatidylinositol 3-kinase; AKT: Protein kinase B; mTOR: Mammalian target of rapamycin; 5-FU: 5-fluorouracil; VEGF: Vascular endothelial growth factor.